ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0509

Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1

Marcela Ferrada1, Keith Sikora2, Sinisa Savic3, Yiming Luo4, Kristina Wells5, Emily Rose1, Kaitlin Quinn6, Wendy Goodspeed1, Anne Jones7, Mimi Le8, Amanda Ombrello9, Zuoming Deng10, Massimo Gadina11, Wanxia Tsai12, Ivona Aksentijevich7, Daniel Kastner13, David Beck14 and Peter C. Grayson15, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institutes of Health Clinical Center, Bethesda, MD, 3University of Leeds, England, United Kingdom, 4Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 5Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 6Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 7National Human Genome Research Institute, Bethesda, MD, 8Oregon Health & Science University, Portland, 9National Institutes of Health, Bethesda, 10National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, 11National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 12National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, MD, 13National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, 14National Human Genome Research Institute, Bethesda, 15Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: cartilage, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA, Behçet’s, & Relapsing Polychondritis (0509–0513)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Relapsing polychondritis (RP) is a rare, heterogenous, systemic inflammatory disease with a predilection for cartilaginous structures. Recently we discovered myeloid-restricted somatic mutations in UBA1 in patients with a spectrum of adult-onset inflammatory diseases, and 60% of these patients were diagnosed with RP. Hematologic mosaicism for variants within a single residue of UBA1 now defines a novel syndrome called VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory,somatic). The study objectives were to determine the prevalence of VEXAS in a cohort of patients with RP, to compare their clinical, laboratory, and immunologic features and to develop a clinical algorithm to inform genetic screening for VEXAS among patients with RP. 

Methods: Patients that met diagnostic criteria for RP and were ≥18 years old were included. All patients were screened by whole-exome sequencing and UBA1 variants of interest were confirmed by Sanger sequencing.  To determine prevalence of VEXAS within RP, UBA1 variants were tested in all patients enrolled in a large, prospective, observational cohort of RP. Additional patients with VEXAS were recruited from other cohorts and included in subsequent analyses. Immune populations were quantified by multipanel flow cytometry. Categorical and continuous variables were compared using the chi square or Kruskal-Wallis test. Random forest was used to create an algorithm to identify patients with VEXAS based on key clinical features. P< 0.05 defined statistical significance.

Results: Within a prospective cohort of 92 patients with RP, 7 patients were confirmed to have UBA1 variants consistent with VEXAS (prevalence=8%). Six additional patients with VEXAS from other cohorts were included for subsequent analyses. Compared to RP, patients with VEXAS were all male, older at disease onset, and more likely to have fever, ear chondritis, periorbital edema, skin involvement, deep vein thrombosis, and pulmonary infiltrates. Patients with RP as compared with VEXAS had a significantly higher prevalence of airway chondritis, costochondritis, tenosynovitis/arthralgias, and vestibular symptoms (Table). Mortality was significantly greater in VEXAS than RP (27% vs 2% p=0.01). Maximum ESR, CRP, and mean corpuscular volume (MCV) values were significantly greater in VEXAS. Absolute monocyte, lymphocyte, and platelet counts were significantly lower in VEXAS. Reduction of B lymphocytes and nonclassical monocytes (CD14-/CD16+) relative to healthy controls was observed in both RP and VEXAS, but was more marked in VEXAS. Increased Th17 cells was observed only in RP. A decision tree based on 1) Male sex or age at onset >50,  2) MCV >100 and 3) platelet count< 200 classified between VEXAS and RP with 100% sensitivity and 96% specificity.

Conclusion: Mutations in UBA1 are causal for disease in 8% of patients with RP. These patients have unique clinical characteristics that readily distinguish them from other patients with RP. A screening algorithm based on four, easily measurable clinical variables differentiates between VEXAS and RP with near-perfect accuracy. Early disease detection and improved clinical management is important in VEXAS given the high rate of mortality in this genetic subset of RP.


Disclosure: M. Ferrada, None; K. Sikora, None; S. Savic, Novartis, 5, 8, SOBI, 2, 5, 8; Y. Luo, None; K. Wells, None; E. Rose, None; K. Quinn, None; W. Goodspeed, None; A. Jones, None; M. Le, None; A. Ombrello, None; Z. Deng, None; M. Gadina, None; W. Tsai, None; I. Aksentijevich, None; D. Kastner, None; D. Beck, None; P. Grayson, None.

To cite this abstract in AMA style:

Ferrada M, Sikora K, Savic S, Luo Y, Wells K, Rose E, Quinn K, Goodspeed W, Jones A, Le M, Ombrello A, Deng Z, Gadina M, Tsai W, Aksentijevich I, Kastner D, Beck D, Grayson P. Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1 [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/classification-of-patients-with-relapsing-polychondritis-based-on-somatic-mutations-in-uba1/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/classification-of-patients-with-relapsing-polychondritis-based-on-somatic-mutations-in-uba1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology